Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373188 · ClinicalTrials.gov registry record · Phase 1
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03373188 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 10 participants.
The verdict
NCT03373188, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This randomized phase I trial studies how well anti-semaphorin 4D (anti-SEMA4D) monoclonal antibody VX15/2503 with or without ipilimumab or nivolumab work in treating patients with stage I-III pancreatic cancer that can be removed by surgery or stage IV colorectal cancer that has spread to the liver and can be removed by surgery. Monoclonal antibodies, such as anti-SEMA4D monoclonal antibody VX15/2503, ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and spread.
Interventions
- BIOLOGICAL Nivolumab
- PROCEDURE Surgery
- BIOLOGICAL Ipilimumab
- BIOLOGICAL Anti-SEMA4D Monoclonal Antibody VX15/2503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2021-10-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03373188
The ClinicalTrials.gov registry entry for NCT03373188 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT03373188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03373188 about?
NCT03373188 is a clinical study titled "VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer". This randomized phase I trial studies how well anti-semaphorin 4D (anti-SEMA4D) monoclonal antibody VX15/2503 with or without ipilimumab or nivolumab work in treating patients with stage I-III pancreatic cancer that can be removed by surgery or stage IV colorectal cancer that has spread to the liver...
What is the current status of trial NCT03373188?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-12-15. Estimated completion is 2021-10-28.
What interventions are being tested in trial NCT03373188?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Surgery (PROCEDURE), Ipilimumab (BIOLOGICAL), Anti-SEMA4D Monoclonal Antibody VX15/2503 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03373188?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.